Supplementary Material

Table S1. Experiences around Patient Enquiries and Prescribing (n=505)

Experience		n=505	%
MC Enquiries in past 3 Months	Nil	74	14.7
	1-4	280	55.4
	5-9	103	20.4
	10-19	30	5.9
	20 or more	18	3.6
Comfortable Discussing Enquiries	Yes	264	52.3
	No	241	47.7
MC Prescriber	Yes	110	21.8
	No	395	78.2
Prescriptions in Past 3 Months	0	410	81.2
	1-9	66	13.1
	10-19	15	3.0
	20-49	11	2.2
	50 or more	3	0.6
Type of Prescriptions	Repeat	43	8.5
	New Prescription	67	13.3
Product Type (THC and/or CBD)	THC Dominant	30	5.9
	CBD Dominant	79	15.6
	THC and CBD Combination	78	15.4
Distinct Products Prescribed	1	36	7.1
	2	21	4.2
	3	24	4.8
	4	12	2.4
	More than 5	17	3.4
Formulation Types Prescribed	Capsules	12	2.4
	Oil	104	20.6
	Sprays	9	1.8
	Flower (flos, plant material)	29	5.7
	Other oral products e.g., tablets, lozenges	3	0.6
MC Prescribing Pathway Used	Special-Access Scheme B	92	18.2
	Authorised Prescriber Scheme	38	7.5
Are Pathways User Friendly?	Yes	55	10.9
	No	55	10.9
Support for Legal cannabis	Medicinal	72	14.3
	Recreational	0	0
	Both	38	7.5

MC: Medicinal cannabis.

Table S2. Indications that prescribers have treated with medicinal cannabis (n=110, valid percentage)

MC Prescribed for Condition	N=110	%
Chronic Non-Cancer Pain	102	92.7
Anxiety	72	65.5
Neuropathic Pain	68	61.8
Insomnia	51	46.4
PTSD	43	39.0
Chronic Cancer Pain	42	38.2
Depression	35	32.0
End of Life/Palliative Care	28	25.5
Chemotherapy-Induced Nausea and Vomiting	19	17.3
Spasticity in Multiple Sclerosis	16	14.5
Other	13	11.8
Dementia Patients with Agitation	10	9.1
Intractable Epilepsy	7	6.4
Cachexia Associated with Severe Illness	6	5.5
Anti-Tumour Effects	3	2.7

MC: Medicinal cannabis; PTSD: Post-traumatic stress disorder.

Table S3. χ^2 Test Values for each of the Knowledge questions in the GP Survey

Knowledge Question Number	Topic	χ^2 Test Value
Questions 1	Knowledge	$(\chi^2(2) =120.5, p<0.001)$
Questions 2	AMA	$(\chi^2(2) =33.6, p<0.001)$
Questions 3	RACGP	$(\chi^2(2) =35.8, p<0.001)$
Questions 4	MC formulations	$(\chi^2(2) =88.8, p<0.001)$
Questions 5	Helping patients	$(\chi^2(2) =83.6, p<0.001)$

Table S4. Differences in support for common MC indications between the current survey and the original survey (Karanges et al., 2018)

Indication	% Support Current Survey (N=505)	% Support Original Survey (N=640)	% Difference
Anxiety	49.3	13	36.3
Insomnia	47.4	13.2	34.2
PTSD	50.9	19	31.9
Chronic Non-Cancer Pain	70.3	39.1	31.2
Neuropathic Pain	66.9	38.3	28.6
Depression	37.2	9.4	27.8
CINV	86.7	64.7	22
Cachexia	73.5	56.7	16.8
End of Life/Palliative Care	92.7	78.8	13.9
Intractable Epilepsy	83.3	70.3	13
Chronic Cancer Pain	91.9	80.2	11.7
Dementia with Agitation	50.9	40.2	10.7
Spasticity in MS	69.1	61.2	7.9

Section 1 - Anonymous demographic information

Age category	◯ Under 24
	◯ 25-34
	◯ 35-44
	◯ 45-54
	◯ 55-64
	◯ Over 65

Gender	◯ Male
	◯ Female
	◯ Other

State/Territory of your practice	◯ NSW
	◯ VIC
	◯ QLD
	◯ SA
	◯ TAS
	◯ WA
	◯ ACT
	◯ NT

Are you a GP registrar?	◯ Yes
	◯ No

Years in General Practice	◯ Less than 1
	◯ 1 - 4
	◯ 5 - 9
	◯ 10 - 14
	◯ 15 - 19
	◯ 20 - 24
	◯ 25 - 29
	◯ More than 30

Average hours spent in clinical practice per week	◯ Less than 10
	◯ 11 - 20
	◯ 21 - 30
	◯ 31 - 40
	◯ More than 40

How many GPs work at your practice?	◯ 1
	◯ 2 - 4
	◯ 5 - 9
	◯ 10 - 20
	◯ More than 20

Geographical area serviced (Select all that apply)	☐ Metro
	☐ Regional
	☐ Remote

What is the post code of the practice where you work?
(Optional)

_____

Section 2 - Medicinal cannabis experience

In the past 3 months, how many of your patients have enquired about medicinal cannabis products?
- ☐ 0
- ☐ 1-4
- ☐ 5-9
- ☐ 10-19
- ☐ 20+

Do you feel comfortable discussing medicinal cannabis as a treatment option with your patients?
- ○ Yes
- ○ No

Have you prescribed medicinal cannabis?
- ○ Yes
- ○ No

In the past 3 months, how many medicinal cannabis prescriptions have you provided?
- ○ 0
- ○ 1-9
- ○ 10-19
- ○ 20-49
- ○ 50-99
- ○ 100-149
- ○ 150+

Are the majority of your medicinal cannabis prescriptions repeats or new prescriptions?
- ○ Repeats
- ○ New Prescriptions

What type of medicinal cannabis products have you prescribed? (Tick all that apply)
- ☐ THC dominant (Schedule 8)
- ☐ CBD dominant (Schedule 4)
- ☐ THC & CBD combination (Schedule 8)

How many distinct medicinal cannabis products do you currently prescribe?
- ○ 1
- ○ 2
- ○ 3
- ○ 4
- ○ More than 5

What formulations of medicinal cannabis have you prescribed? (Tick all that apply)
- ☐ Capsules
- ☐ Oil
- ☐ Sprays
- ☐ Flower (Flos, plant material)
- ☐ Other oral products e.g., tablets, lozenges

How have you prescribed medicinal cannabis products? (Tick all that apply)
- ☐ Special-Access Scheme B
- ☐ Authorised Prescriber Scheme

Do you believe the TGA approval process for medicinal cannabis is doctor-friendly?
- ○ Yes
- ○ No

Do you believe cannabinoids should be legally available for the following purposes?
- ○ Medicinal
- ○ Recreational
- ○ Both

I have prescribed medicinal cannabis products for the following conditions (tick all that apply)	☐ Chronic cancer pain
	☐ Chronic non-cancer pain
	☐ Neuropathic pain
	☐ Intractable epilepsy
	☐ End of life/Palliative care
	☐ Chemotheraphy-induced nausea and vomiting
	☐ Cachexia associated with severe illness
	☐ Anti-tumour effects
	☐ Spasticity in Multiple Sclerosis
	☐ Dementia patients with agitation
	☐ Insomnia
	☐ PTSD
	☐ Anxiety
	☐ Depression
	☐ Other (please specify)

Other, please specify

_____

Please indicate how much you agree or disagree with each of the following statements

	Strongly Agree	Slightly Agree	Neutral	Slightly Disagree	Strongly Disagree
I know how to help patients legally access medicinal cannabis	○	○	○	○	○
I am aware of the different medicinal cannabis products and formulations currently available	○	○	○	○	○
I understand the current RACGP position on medicinal cannabis	○	○	○	○	○
I understand the current AMA position on medicinal cannabis	○	○	○	○	○
I am supportive of CBD products available over the counter in pharmacies	○	○	○	○	○
Medicinal cannabis should only be prescribed by GPs in conjunction with specialists	○	○	○	○	○
Only GPs who have undergone specific training and credentialing should be allowed to prescribe medicinal cannabis	○	○	○	○	○
There is sufficient scientific evidence on the efficacy of medicinal cannabis	○	○	○	○	○

When considering prescribing medicinal cannabis

	Strongly agree	Slightly agree	Neutral	Slightly disagree	Strongly disagree
The risk of side effects is too high	○	○	○	○	○
The risk of abuse and dependence is too high	○	○	○	○	○
I am concerned about the effects on driving	○	○	○	○	○
I am concerned about drug seeking patients	○	○	○	○	○
I do not have enough knowledge of its application in clinical practice	○	○	○	○	○
The prescribing process is too difficult	○	○	○	○	○
I am not convinced of the clinical efficacy	○	○	○	○	○
It is too costly	○	○	○	○	○
There is sufficient scientific evidence on the efficacy of medicinal cannabis	○	○	○	○	○

I support the use of medicinal cannabis products in patients with

	Strongly agree	Slightly agree	Neutral	Slightly disagree	Strongly disagree
Chronic cancer pain	○	○	○	○	○
Chronic non-cancer pain	○	○	○	○	○
Neuropathic pain	○	○	○	○	○
Intractable epilepsy	○	○	○	○	○
End of life/Palliative care	○	○	○	○	○
Chemotheraphy-induced nausea and vomiting	○	○	○	○	○
Cachexia associated with severe illness	○	○	○	○	○
Anti-tumour effects	○	○	○	○	○
Spasticity in Multiple Sclerosis	○	○	○	○	○
Dementia patients with agitation	○	○	○	○	○
Insomnia	○	○	○	○	○
PTSD	○	○	○	○	○
Anxiety	○	○	○	○	○
Depression	○	○	○	○	○

The major concerns with THC containing products include:

	Strongly agree	Slightly agree	Neutral	Slightly disagree	Strongly disagree
Addiction and dependence	○	○	○	○	○
Cognitive impairment	○	○	○	○	○
Driving impairment	○	○	○	○	○
Weight gain	○	○	○	○	○
Psychosis	○	○	○	○	○
Other long-term mental health issues	○	○	○	○	○
Interactions with other medications	○	○	○	○	○
Impact on the developing brain	○	○	○	○	○
Lack of Efficacy	○	○	○	○	○

The major concerns with CBD containing products include:

	Strongly agree	Slightly agree	Neutral	Slightly disagree	Strongly disagree
Addiction and dependence	○	○	○	○	○
Cognitive impairment	○	○	○	○	○
Driving impairment	○	○	○	○	○
Weight gain	○	○	○	○	○
Psychosis	○	○	○	○	○
Other long-term mental health issues	○	○	○	○	○
Interactions with other medications	○	○	○	○	○
Impact on the developing brain	○	○	○	○	○
Lack of Efficacy	○	○	○	○	○

Medicinal cannabis is generally more hazardous than:

	Strongly agree	Slightly agree	Neutral	Slightly disagree	Strongly disagree
Prescription opioids	○	○	○	○	○
Benzodiazepines	○	○	○	○	○
Antipsychotics	○	○	○	○	○
Statins	○	○	○	○	○
Chemotherapy drugs	○	○	○	○	○
Antidepressants	○	○	○	○	○

Please provide any further comments, questions or
opinions about medicinal cannabis in Australia

_____

REDCap